2025
TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
Ong M, Sokolova A, Hotte S, Dorff T, Chi K, Wyatt A, Goldkorn A, Kolinsky M, Brundage M, Ndika A, Lerner S, Parulekar W, Ding K, Jafri M. TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps5129.Peer-Reviewed Original ResearchMetastatic castration sensitive prostate cancerAndrogen receptor pathway inhibitorsAndrogen deprivation therapyPSA responseOverall survivalDisease volumePredictive value of circulating tumor DNADocetaxel to androgen deprivation therapyReceipt of androgen deprivation therapyResponse to androgen deprivation therapyMonths of androgen deprivation therapyAndrogen deprivation therapy initiationCastration sensitive prostate cancerClinical progression free survivalMonths median overall survivalStandard androgen deprivation therapyECOG performance status 0Pathway inhibitorRandomized phase III trialPresence of liver metastasesAbsence of randomized dataRandomized phase III clinical trialsPrimary prostate cancer tissuesNational Clinical Trials NetworkPhase III clinical trials
2009
Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy
Choueiri T, Xie W, D'Amico A, Ross R, Hu J, Pomerantz M, Regan M, Taplin M, Kantoff P, Sartor O, Oh W. Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy. Cancer 2009, 115: 981-987. PMID: 19152438, PMCID: PMC2931827, DOI: 10.1002/cncr.24064.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapy initiationProstate-specific antigen nadirHormone-sensitive prostate cancerMetastatic hormone-sensitive prostate cancerAndrogen deprivation therapyProstate-specific antigenInitiation of androgen deprivation therapyTreated with androgen deprivation therapyGleason score >7Overall survivalPSA declineShorter OSProstate cancerKinetics of prostate-specific antigenResponse to ADTNadir prostate-specific antigenProstate-specific antigen declineAssociated with shorter OSAssociated with shorter survival durationMedian PSA levelSerum PSA valuesSerum PSA determinationMedian Follow-UpAuthors' institutional databaseShorter survival duration
2008
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
Ross R, Xie W, Regan M, Pomerantz M, Nakabayashi M, Daskivich T, Sartor O, Taplin M, Kantoff P, Oh W. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. Cancer 2008, 112: 1247-1253. PMID: 18293426, DOI: 10.1002/cncr.23304.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAndrogen AntagonistsCohort StudiesDisease ProgressionFollow-Up StudiesGonadotropin-Releasing HormoneHumansMaleMiddle AgedNeoplasm StagingNeoplasms, Hormone-DependentOrchiectomyProstate-Specific AntigenProstatectomyProstatic NeoplasmsRetrospective StudiesSurvival RateConceptsEfficacy of androgen deprivation therapyAndrogen deprivation therapy initiationAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerProstate cancerGleason scoreDeprivation therapyM+ patientsLower serum prostate-specific antigenUse of androgen deprivation therapyCohort of prostate cancer patientsLower biopsy Gleason scoreSerum prostate-specific antigenMetastatic disease statusBiopsy Gleason scoreAdvanced prostate cancerAbsence of metastasesProstate cancer patientsShortened TTPMedian TTPLocal therapyDecreased TTPM patientsRetrospective study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply